UNLIMITED TURBO BULL - ASTRAZENECA | Real-time Euronext Paris 13:49:46 17/05/2024 BST | ||
| 4.655 EUR | +0.11% |
|
| Current month | +2.65% | ||
| 1 month | +42.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 4.655 | +0.11% |
| 16/05/24 | 4.65 | -0.64% |
| 15/05/24 | 4.68 | -2.09% |
| 14/05/24 | 4.78 | -0.62% |
| 13/05/24 | 4.81 | -0.72% |
Real-time Euronext Paris
Last update May 17, 2024 at 01:49 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| 63Q4S | |
| ISIN | DE000SV79UC1 |
| Date issued | 04/07/2023 |
| Strike | 8,185 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.975 € |
|---|---|
| Lowest since issue | 1.625 € |
| Spread | 0.01 € |
| Spread % | 0.22% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
154.2
USD
Average target price
167.6
USD
Spread / Average Target
+8.70%
- Stock Market
- Certificates
- 63Q4S Certificat
